RESUMEN
The morbidity and mortality of pancreatic cancer are increasing year by year, and the risk of venous thromboembolism (VTE) in patients with pancreatic cancer is significantly increased, especially in the local advanced stage, metastatic stage and chemotherapy period. The patient's condition is often complicated by VTE events, which further increases the risk of death. This article reviews the latest literature, discusses the occurrence, development and clinical outcome of VTE in patients with pancreatic cancer, and introduces the research progress of pancreatic cancer VTE from the perspective of epidemiology, pathophysiology, clinical manifestations, prevention and treatment strategies.
RESUMEN
AIM: To explore the role of clinical pharmacists in the establishment of standardized cancer pain management ward in our hospital. METHODS: Information of hospitalized patients with cancer pain admitted to the oncology department from January to June 2018 and from July to December 2018 was retrospectively collected and was allocated as the control group and the intervention group, respectively. A total of 114 patients were included in the study, including 58 in the control group and 56 in the intervention group. General information included gender, age, body mass index, tumor type, KPS score, NRS score, etc was collected. There was no statistical difference of the baseline value. The analgesic effect before and after clinical pharmacists' participation was compared. RESULTS: The pain score in the intervention group was significantly lower than that in the control group (P<0.05), the number of pain occurence in the intervention group was significantly lower than that in the control group (P<0.05), and the total incidence of adverse reactions in the intervention group was significantly lower than that in the control group (P<0.05), and KPS score in the intervention group was significantly higher than that in the control group (P<0.05). CONCLUSION: Participant of clinical pharmacists in the diagnosis and treatment of standardized cancer pain ward elevates the standardized treatment level of cancer pain and improves the life qualityof cancer patients.
RESUMEN
Objective To explore the recurrence-prevention effect of oral contraceptive and levonorgestrel-releasing intrauterine system (Mirena) after hysteroscopic endometrial polypectomy.Methods One hundred and seventy-four patients who received hysteroscopic endometrial polypectomy were enrolled in this research.The patients were informed and divided into three groups according to their selection:51 cases were given oral contraceptive since one month until 12 months after the surgery (oral contraceptive group); 60 cases were received Mirena since one month after the surgery (Mirena group) ; and 64 cases were received no treatment after the surgery (control group).The groups were followed up at 3,6,12 months after the surgery and compared the recurrence rate,menstruation,level of hemoglobin and complication rate.Results The recurrence rate in oral contraceptive group,Mirena group and control group was 3.9％(2/51),3.3％ (2/60) and 19.0％ (12/63),respectively.The recurrence rate in control group was higher than that in oral contraceptive group and Mirena group,and there was significant difference (P ＜ 0.05).The proportion of low menstruation volume in control group was lower than that in oral contraceptive group and Mirena group,and there was significant difference (P ＜ 0.05).The level of hemoglobin in control group was lower than that in oral contraceptive group and Mirena group [(124.55 ±9.33) g/L vs.(133.71 ± 11.03),(135.89 ±6.88) g/L],and there was significant difference (P ＜ 0.05).The incidence of complication in Mirena group [18.3％ (11/60)] was less than that in oral contraceptive group[35.3％(18/51)],and there was significant difference (P ＜ 0.05).Conclusions Oral contraceptive and Mirena after hysteroscopy for endometrial polys significantly decrease the recurrence rate.The complication rate of Mirena is lower and it is a safe and effective way to treat and prevent the endometrial polyp.